Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2Phase 3 1Phase 1/2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

NET 2Gastrointestinal 2Endocrine 2CNS 1

Conditions

Neuroendocrine Tumors 15Paraganglioma 4Meningioma 4Carcinoma, Neuroendocrine 4Pheochromocytoma 3Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Medullary 2Carcinoid Tumor 2Somatostatinoma 1Serotonin Syndrome 1Prostatic Neoplasms 1Pituitary Neoplasms 1Parathyroid Neoplasms 1Neuroblastoma 1Neoplasms 1Metastatic Digestive System Neuroendocrine Tumor G1 1Hypertension 1Disease Progression 1Carcinoma, Merkel Cell 1Carcinoid Heart Disease 1Breast Neoplasms 1Advanced Lung Neuroendocrine Tumor 1Adenoma, Islet Cell 1

Interventions

lutetium Lu 177 dotatate 2copper dotatate CU-64 2Etoposide 2zimberelimab 1folfirinox 1famitinib 1cabozantinib 1abemaciclib 1Temozolomide 1Nivolumab 1Lutetium-177 1Lutetium 1Irinotecan 1Granulocyte Colony-Stimulating Factor 1Fluorodeoxyglucose F18 1Filgrastim 1Cytokines 1Cryotherapy 1Copper 1Cisplatin 1Carboplatin 1Acupuncture Therapy 1Acupressure 164Cu-DOTATATE 1177Lu-octreotide, DOTA(0)-Tyr(3)- 111-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Gastro-enteropancreatic neuroendocrine tumor × lutetium Lu 177 dotatate × Clear all
NCT04711135 2026-02-12

NETTER-P

Advanced Accelerator Applications

Phase 2 Active not recruiting
11 enrolled 14 charts 1 FDA
CNSEndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Paraganglioma, Pheochromocytoma

NCT05987176 2026-01-14

NELMAS

Imperial College London

Phase 2 Terminated
1 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡